{"id":245865,"date":"2026-05-14T05:49:14","date_gmt":"2026-05-14T05:49:14","guid":{"rendered":"https:\/\/www.europesays.com\/se\/245865\/"},"modified":"2026-05-14T05:49:14","modified_gmt":"2026-05-14T05:49:14","slug":"oncopeptides-presenterar-nya-kliniska-data-for-pepaxti-vid-massa-i-paris","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/se\/245865\/","title":{"rendered":"Oncopeptides presenterar nya kliniska data f\u00f6r Pepaxti vid m\u00e4ssa i Paris"},"content":{"rendered":"<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">Forskningsbolaget Oncopeptides meddelar att nya data som st\u00f6djer den kliniska nyttan av Pepaxti (melflufen) vid relapserande, refrakt\u00e4rt multipelt myelom (RRMM) kommer att presenteras vid den 12:e World Congress on Controversies in Myltiple Myeloma (COMy), som \u00e4ger rum i Paris, Frankrike, 14\u201317 maj.\n <\/p>\n<p>\u201dVi \u00e4r glada \u00f6ver att kunna presentera en robust upps\u00e4ttning data vid COMy som bekr\u00e4ftar resultaten fr\u00e5n v\u00e5ra egna kliniska pr\u00f6vningar kombinerat med insikter fr\u00e5n klinisk praxis\u201d, s\u00e4ger Stefan Norin, Chief Medical Officer p\u00e5 Oncopeptides.\n <\/p>\n<p>\u201dStabiliteten i njurfunktionen som observerats i v\u00e5r poolade analys, i kombination med den uppmuntrande aktivitet som ses i den spanska registerstudien \u2013 \u00e4ven hos patienter som tidigare behandlats med BCMA-riktade l\u00e4kemedel \u2013 forts\u00e4tter att validera Pepaxti som ett viktigt behandlingsalternativ f\u00f6r patienter med stora medicinska behov.\u201d<br \/>\n <br class=\"col-start-2\"\/><\/p>\n<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">Nyhetsbyr\u00e5n Finwire<\/p>\n","protected":false},"excerpt":{"rendered":"Forskningsbolaget Oncopeptides meddelar att nya data som st\u00f6djer den kliniska nyttan av Pepaxti (melflufen) vid relapserande, refrakt\u00e4rt multipelt&hellip;\n","protected":false},"author":2,"featured_media":218265,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[65],"tags":[72,70,71,6576,34,31,33,32,30],"class_list":["post-245865","post","type-post","status-publish","format-standard","has-post-thumbnail","category-ekonomi","tag-business","tag-economy","tag-ekonomi","tag-oncopeptides","tag-se","tag-svenska","tag-sverige","tag-sweden","tag-swedish"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@se\/116571364632690155","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/245865","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/comments?post=245865"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/245865\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media\/218265"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media?parent=245865"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/categories?post=245865"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/tags?post=245865"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}